Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis

Pediatric Pulmonology
Matthew E FalagasDimitris A Kafetzis

Abstract

Data regarding the role of inhaled colistin in critically ill pediatric patients without cystic fibrosis are scarce. Three children (one female), admitted to the intensive care unit (ICU) of a tertiary-care pediatric hospital in Athens, Greece, during 2004-2009 received inhaled colistin as monotherapy for tracheobronchitis (two children), and as adjunctive therapy for necrotizing pneumonia (one child). Colistin susceptible Acinetobacter baumannii and Pseudomonas aeruginosa were isolated from the cases' bronchial secretions specimens. All three children received inhaled colistin at a dosage of 75 mg diluted in 3 ml of normal saline twice daily (1,875,000 IU of colistin daily), for a duration of 25, 32, and 15 days, respectively. All three children recovered from the infections. Also, a gradual reduction, and finally total elimination of the microbial load in bronchial secretions was observed during inhaled colistin treatment in the reported cases. All three cases were discharged from the ICU. No bronchoconstriction or any other type of toxicity of colistin was observed. In conclusion, inhaled colistin was effective and safe for the treatment of two children with tracheobronchitis, and one child with necrotizing pneumonia. Furthe...Continue Reading

References

Sep 12, 1998·Annals of Internal Medicine·D J CookC Brun-Buisson
Apr 24, 2001·Archives of Disease in Childhood·S CunninghamC Wallis
Jun 14, 2001·Journal of Clinical Pharmacology·M D ReedJ L Blumer
Oct 3, 2002·The European Respiratory Journal·M E HodsonJ R W Govan
Mar 9, 2004·European Journal of Clinical Pharmacology·Federico MarchettiBaroukh M Assael
Jan 22, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·David BerlanaR Jódar
Feb 8, 2005·Critical Care : the Official Journal of the Critical Care Forum·Argyris MichalopoulosMatthew E Falagas
Feb 12, 2005·Chest·Ghassan A AlothmanAllan L Coates
Jan 7, 2006·The Journal of Antimicrobial Chemotherapy·F RatjenH Grasemann
Feb 21, 2007·Expert Opinion on Pharmacotherapy·Jennifer K HagermanMichael E Klepser
Dec 7, 2007·Canadian Respiratory Journal : Journal of the Canadian Thoracic Society·Marie-Sophie BrochetJacques-Edouard Marcotte
Apr 29, 2008·Clinics in Chest Medicine·Rajiv Dhand, Vamsi P Guntur
Jun 17, 2008·Critical Care Medicine·Lucy B PalmerPaul Richman
Dec 5, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Paul Checchia
Jan 1, 2009·The Pediatric Infectious Disease Journal·Matthew E FalagasDimitris A Kafetzis
Jan 3, 2009·Respiratory Medicine·Matthew E FalagasArgyris Michalopoulos
Jan 27, 2009·International Journal of Antimicrobial Agents·Matthew E FalagasPetros I Rafailidis
Sep 1, 2009·American Journal of Surgery·Matthew E FalagasGeorge Peppas

❮ Previous
Next ❯

Citations

Jul 19, 2011·International Journal of Clinical Practice·G TheocharisM E Falagas
Sep 14, 2013·Journal of Postgraduate Medicine·A K Dhariwal, M S Tullu
Feb 16, 2012·Expert Opinion on Drug Delivery·Sabina Antonela Antoniu, Ileana Cojocaru
May 27, 2016·Clinical Microbiology Reviews·Eric WenzlerLarry H Danziger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.